AGS-1C4D4

Astellas Pharma Inc · Phase 2 active Small molecule

At a glance

Generic name	AGS-1C4D4
Also known as	ASP6182
Sponsor	Astellas Pharma Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 (PHASE2)
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer (PHASE2)
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AGS-1C4D4 CI brief — competitive landscape report
AGS-1C4D4 updates RSS · CI watch RSS
Astellas Pharma Inc portfolio CI